Exclusive Summary

• Backed by dual US-FDA and EU-EMA GMP certifications, ensuring flawless regulatory compliance and rapid market access globally.
• Targets an underserved $100+ billion T2DM and weight-loss market currently suffering from massive global shortages of the originator drug.
• Acts as the best-in-class dual-agonist (GIP/GLP-1) with unprecedented efficacy surpassing Semaglutide, highly endorsed as a first-line treatment in international guidelines.
• Provides globally scarce manufacturing capacity for high-barrier peptide injectables, offering substantial cost advantages and lucrative profit margins for B2B distribution partners.